Assessment of cardiovascular risk on the SCORE and SCORE2 scales among the male population

To assess cardiovascular risk, old methods are being reviewed and new, more objective and easy-to-use methods are being proposed, taking into account new epidemiological, economic and nutritional transformations. This approach allows you to expand the circle of people who need to be monitored. Objective. To compare the level of cardiovascular risk on the SCORE and SCORE2 scales among an almost healthy male population. Object and methods. The study was conducted among the male population aged 40-59 years. 419 people were included. The risk of cardiovascular complications was calculated for each respondent using SCORE and SCORE2. The statistical analysis was carried out in the StatTech v. program. 4.7.1. Results. According to the SCORE scale, the respondents were distributed as follows: in the 40–44–year–old group, 10 subjects were in the low-risk group, 38 were in the moderate group; in the 45–49-year-old group, 59 were in moderate risk, 22 were in high risk, and 1 was in very high risk. In the 50–54-year-old group, 56 were at moderate risk, 40 were at high risk, and 7 were at very high risk. In the 54–59- year-old group, 36 people were in the moderate-risk group, 48 were in the high-risk group, and 34 were in the very high-risk group. On the SCORE2 scale, the same respondents were included in the high- and very high-risk groups. At the same time, the risk of complications increased by 9% (p < 0.001). The respondents with HDL-C levels of less than 3.99 mmol/L on the SCORE scale were distributed as follows: in the 40–44 year group, 3 were in the low–risk group, 6 were in the moderate risk group; in the 45–49 year group, 16 were in the moderate risk group. In the 50–54 year old group, 19 were at moderate risk. In the 54–59-year-old group, 20 people were in the moderate risk group, 4 were at high risk, and 34 were very high. According to the SCORE2 scale, the same respondents were included in the high and very high risk groups. The risk of complications increased by 10% (p < 0.001). Conclusion. The SCORE2 scale makes it possible to assess the risk of cardiac events in a wider range of people, to monitor them more actively in the future, and to expand indications for therapy.